Q-omics provides the consensus-scored SNX2 profile across patient tissues and cancer cell-line models. SNX2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNX2 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, SNX2 protein abundance shows 27,647 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where SNX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX2 survival associations across molecular data types. SNX2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX2 RNA expression–survival associations across cancer types. High SNX2 expression shows unfavorable associations in HNSC, LIHC, ESCA and KICH, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNX2 RNA expression.
This table summarizes SNX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SNX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX2 shows lower tumor expression in LUAD, THCA, LUSC, KICH and COAD and higher tumor expression in LIHC. The LUAD box plot shows higher SNX2 RNA expression in normal versus tumor tissue (log2 FC = −0.949, t-test p < 0.001).
This table shows molecular features associated with SNX2 in patient tissues and cancer cell lines. In patient samples, SNX2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
